GlassScriptPhysician profile
Justin W Clark
NPI 1639164098
$6,177.72
in general payments reported to CMS, 2019-2025
28 companies · $904 in 2025
The $904 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,402 · 2020: $634 · 2021: $671 · 2022: $692 · 2023: $965 · 2024: $910 · 2025: $904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,779.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,778.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,562.79 | 2019-2025 | Skyrizi |
| Amgen INC. | $746.57 | 2020-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $437.81 | 2019-2025 | Tremfya, Stelara, Simponi |
| E.R. Squibb & Sons, L.L.C. | $409.43 | 2019-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $373.11 | 2019-2025 | |
| Leo Pharma INC. | $332.12 | 2022-2024 | Adbry |
| Regeneron Healthcare Solutions, INC. | $281.59 | 2019-2025 | Dupixent |
| Galderma Laboratories, L.P. | $267.49 | 2019-2025 | Aklief, Oracea, Twyneo |
| Ucb, INC. | $220.18 | 2019-2025 | Bimzelx |
| Lilly USA, LLC | $217.10 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $212.26 | 2019-2023 | |
| Janssen Scientific Affairs, LLC | $179.37 | 2019-2020 | |
| Celgene Corporation | $122.94 | 2019 | |
| Incyte Corporation | $118.01 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $108.18 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $105.42 | 2025 | Daxxify |
| Genzyme Corporation | $90.00 | 2019-2024 | |
| Journey Medical Corporation | $70.97 | 2022-2023 | |
| Genentech USA, INC. | $56.92 | 2019-2024 | Xolair |
| Almirall LLC | $47.85 | 2020-2025 | Seysara |
| Mayne Pharma Commercial LLC | $45.12 | 2022-2024 | |
| Organon LLC | $40.14 | 2025 | Vtama |
| Allergan, INC. | $37.70 | 2019-2021 | |
| Convatec INC. | $26.97 | 2024 | |
| Sandoz INC. | $23.01 | 2023 | Hyrimoz |
| Biofrontera INC. | $15.94 | 2019 | |
| Arcutis Biotherapeutics, INC. | $15.73 | 2025 | Zoryve |
| Organogenesis INC. | $13.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.